World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
75
Citations
24618
World Ranking
1964
National Ranking
20

Inge Marie Svane publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Inge Marie Svane sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 473 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Inge Marie Svane D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Inge Marie Svane sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 75 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Inge Marie Svane is affiliated with Copenhagen University Hospital in Denmark. Their research primarily lies within the fields of Medicine and Immunology and Microbiology, with a focus on oncology and immunology subfields. Their work encompasses several subfields including Oncology, Immunology, Molecular Biology, Genetics, and Pulmonary and Respiratory Medicine.

Their main research topics include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, cutaneous melanoma detection and management, melanoma and MAPK pathways, immune cell function and interaction, and virus-based gene therapy research.

Frequent collaborators in their research include Marco Donia, Eva Ellebæk, Lars Bastholt, Özcan Met, and Troels Holz Borch.

They have published extensively in various scientific venues. The most frequent publication venues include:

  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Immuno-Oncology Technology

Selected recent papers authored or co-authored by Svane illustrate the scope and impact of their research:

  • Tertiary lymphoid structures improve immunotherapy and survival in melanoma, 2020, Nature
  • Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma, 2022, New England Journal of Medicine
  • Clinical advances and ongoing trials of mRNA vaccines for cancer treatment, 2022, The Lancet Oncology
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1, 2020, Nature Immunology

Best Publications

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

    Rita Cabrita;Martin Lauss;Adriana Sanna;Marco Donia

  • Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

    Unknown

  • Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

    Unknown

  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Paolo A. Ascierto;Michele Del Vecchio;Caroline Robert;Andrzej Mackiewicz

  • Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

    Martin Lauss;Marco Donia;Katja Harbst;Rikke Andersen

  • Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

    Celeste Lebbé;Nicolas Meyer;Laurent Mortier;Ivan Marquez-Rodas

  • Collagen density regulates the activity of tumor-infiltrating T cells

    Dorota E. Kuczek;Anne Mette Hvid Larsen;Anne Mette Hvid Larsen;Marie-Louise Thorseth;Marco Carretta

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Alexander M M Eggermont;Christian U Blank;Mario Mandalà;Georgina V Long

  • Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

    Amalie Kai Bentzen;Andrea Marion Marquard;Rikke Lyngaa;Sunil Kumar Saini

  • Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

    Paolo A. Ascierto;Georgina V. Long;Georgina V. Long;Caroline Robert;Benjamin Brady

  • Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Paolo Antonio Ascierto;Pier Francesco Ferrucci;Rosalie Fisher;Michele Del Vecchio

  • Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

    Rikke Andersen;Marco Donia;Eva Ellebaek;Troels Holz Borch

  • Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

    Marie Klinge Brimnes;Annette Juul Vangsted;Lene Meldgaard Knudsen;Peter Gimsing

  • Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

    Lotte Engell-Noerregaard;Troels Holz Hansen;Mads Hald Andersen;Per thor Straten

  • Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Michael D. Crowther;Garry Dolton;Mateusz Legut;Marine E. Caillaud

  • The universal character of the tumor-associated antigen survivin.

    Mads Hald Andersen;Inge Marie Svane;Jürgen C. Becker;Per thor Straten

  • Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

    U Dafni;U Dafni;O Michielin;S Martin Lluesma;S Martin Lluesma;Z Tsourti

  • Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

    Y.J.L. Jansen;E.A. Rozeman;R. Mason;S.M. Goldinger

  • Principles of adoptive T cell therapy in cancer.

    Özcan Met;Özcan Met;Kasper Mølgaard Jensen;Christopher Aled Chamberlain;Marco Donia

  • Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

    Eva Ellebaek;Trine Zeeberg Iversen;Niels Junker;Marco Donia;Marco Donia

  • Predictors of responses to immune checkpoint blockade in advanced melanoma.

    N Jacquelot;N Jacquelot;M P Roberti;D P Enot;S Rusakiewicz

Frequent Co-Authors

Mads Hald Andersen
Mads Hald Andersen Copenhagen University Hospital
Marco Donia
Marco Donia Copenhagen University Hospital
Per thor Straten
Per thor Straten University of Copenhagen
Sine Reker Hadrup
Sine Reker Hadrup Technical University of Denmark
Morten Hartvig Hansen
Morten Hartvig Hansen University of Southern Denmark
Jürgen C. Becker
Jürgen C. Becker University of Duisburg-Essen
Göran Jönsson
Göran Jönsson Lund University
Georgina V. Long
Georgina V. Long University of Sydney
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology in the USA opens diverse career avenues, especially when combined with advanced nursing degrees. Many professionals look for programs that balance quality and affordability, such as the cheapest psych np programs online, which offer accessible pathways into specialized healthcare roles.

For those interested in further specialization, understanding the highest paid dnp specialties helps guide career decisions, ensuring a strategic focus on both impact and financial reward. Transitioning between nursing roles is also common, with resources available to support shifts such as the fnp to acute care certification, which prepares nurses to handle complex cases linked to immunological conditions.

Accelerated pathways like the accelerated rn to np programs enable students with foundational nursing backgrounds to quickly advance their qualifications, making it easier to enter immunology-related specialties backed by nurse practitioner credentials. These combined options highlight the flexibility and breadth of study and career growth in immunology and healthcare.

Best Scientists Citing Inge Marie Svane

Trending Scientists

Recently Published Articles